帝科股份(300842.SZ):一項目獲省級戰略性新興產業發展專項資金1600萬元
格隆匯1月11日丨帝科股份(300842.SZ)公佈,公司於近日收到宜興市發展和改革委員會宜興市財政局下發的《關於下達2021年度省級戰略性新興產業發展專項資金及項目投資計劃的通知》(宜發改產業〔2022〕4號),公司的“無錫帝科電子材料股份有限公司年產500噸正面銀漿搬遷及擴能建設產業化項目”被列入2021年度江蘇省戰略性新興產業發展專項資金建議立項項目和資金安排計劃表,預計可獲得支持金額1600萬元,佔公司最近一個會計年度經審計的歸屬於上市公司股東淨資產的1.92%。
上述政府補助與公司日常經營活動有關,不具有可持續性。截至該公吿披露日,公司尚未收到上述補助款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.